Weekly Paclitaxel for Ovarian Cancer Treatment
Author Information
Author(s): Kenny LM, McDermott U, Atkinson RJ
Primary Institution: N.Ireland Cancer Centre, Belfast, UK
Hypothesis
To study the efficacy and toxicity of weekly paclitaxel in patients with recurrent epithelial ovarian cancer previously treated with platinum-based therapy.
Conclusion
Weekly paclitaxel is an effective and well-tolerated treatment for platinum-pretreated patients with recurrent ovarian carcinoma.
Supporting Evidence
- 19 out of 40 patients had partial response or stable disease.
- Median progression-free survival was 8.5 months.
- Only 12% of patients experienced grade 3 toxicity.
Takeaway
This study shows that giving paclitaxel every week can help women with a certain type of ovarian cancer feel better and have fewer side effects.
Methodology
A retrospective audit of 40 patients treated with weekly paclitaxel, assessing progression-free survival, toxicity, and cost.
Limitations
The study is retrospective and may not account for all variables affecting outcomes.
Participant Demographics
Mean age was 58 years, with a range of 44-80 years; 45% were optimally debulked at initial surgery.
Statistical Information
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website